Sumant Ramachandra
CancerVax Inc., a Lehi-based developer of a cancer treatment platform that will use the body’s immune system to fight cancer, named Dr. Sumant Ramachandra as chief scientific advisor. Ramachandra founded SR Global Health LLC, a health care advisory firm. Ramachandra serves as a director on the board of Lyell Immunopharma following Lyell’s acquisition of ImmPACT Bio in October. He was CEO of ImmPACT from November 2021 until its acquisition. Ramachandra also serves as an advisor to private equity funds on companies in the pharmaceuticals, biotechnology and medical devices/software sectors. Earlier in his career, he served as chief science, technology and medical officer at Baxter International; president of Baxter Pharmaceuticals; senior vice president, head of research and development at Pfizer Essential Health; chief scientific officer at Hospira; and he held senior roles at Pfizer and Merck & Co. He began his medical career as an intern and resident physician at Massachusetts General Hospital, Harvard Medical School.
